Resomelagon is under clinical development by SynAct Pharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Resomelagon’s likelihood of approval (LoA) and phase transition for Inflammatory Bowel Disease took place on 10 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 10 May 2022 increased Resomelagon’s Phase Transition Success Rate (PTSR) for Peritonitis.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Resomelagon Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Resomelagon overview

Resomelagon is under development for the treatment of systemic inflammatory diseases such as psoriatic arthritis, rheumatoid arthritis, inflammatory bowel diseases, peritonitis, systemic lupus erythematosus, multiple sclerosis, nephrotic syndrome and acute respiratory distress syndrome (ARDS) associated with coronavirus COVID-19. The drug candidate is administered orally. It is a phenyl pyrrole aminoguanidine derivative. AP-1189 is an anti-inflammatory compound. It acts as a positive allosteric modulator (PAM) of the melanocortin receptors.

SynAct Pharma overview

SynAct Pharma is a biotechnology company. The company focuses on the development of drugs to treat acute aggravation of inflammatory diseases. Its lead drug candidate, AP1189, is being developed for the treatment of psoriatic arthritis. SynAct Pharma designed its proprietary platform technology platform based on a new class of drugs, which target inflammation and bolster the body’s cells to reduce acute symptoms and stimulate the natural healing mechanisms. The company plans to initiate a Phase two study to evaluate the safety and efficacy of AP1189 in patients with psoriatic arthritis. SynAct Pharma is headquartered in Lund, Sweden.

Quick View Resomelagon LOA Data

Report Segments
  • Innovator
Drug Name
  • Resomelagon
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Immunology
  • Infectious Disease
  • Musculoskeletal Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.